Watchlist Price Alert

Monte Rosa Therapeutics I... (GLUE)

NASDAQ: GLUE · Real-Time Price · USD

4.08

-0.14 (-3.32%)

At close: May 09, 2025, 3:59 PM

4.14

1.47%

After-hours: May 09, 2025, 04:40 PM EDT

-3.32% (1D)

Bid	4.01
Market Cap	250.96M
Revenue (ttm)	75.62M
Net Income (ttm)	-72.7M
EPS (ttm)	-0.98
PE Ratio (ttm)	-4.16
Forward PE	-2.36
Analyst	Buy

Ask	4.23
Volume	368,452
Avg. Volume (20D)	691,739
Open	4.24
Previous Close	4.22
Day's Range	4.06 - 4.59
52-Week Range	3.21 - 12.40
Beta	1.52

About GLUE

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol GLUE

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for GLUE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Monte Rosa Therapeutics has released their quartely earnings on May 8, 2025:

Revenue of $84.93M exceeds estimates by $71.36M, with 7882.05% YoY growth.

EPS of 0.57 exceeds estimates by 0.89, with 207.55% YoY growth.

Why Price Moved

6 months ago

+93.87%

Monte Rosa Therapeutics shares are trading higher ... Unlock content with Pro Subscription

News

1 day ago · zacks.com

Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year a...

1 month ago · seekingalpha.com

Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic ...

1 month ago · zacks.com

Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year a...

2 months ago · zacks.com

3 Top Cancer Biotechs to Keep An Eye On in 2025

If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.

2 months ago · seekingalpha.com

Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN

One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partn...